AG
MRSN

Artal Group’s Mersana Therapeutics MRSN Stock Holding History

Artal Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-121,182
Closed -$9.97M – 113
2023
Q2 		$9.97M Buy
121,182
+32,550
+37% +$4.76M 0.32% 49
2023
Q1 		$9.11M Buy
88,632
+632
+0.7% +$88.7K 0.54% 44
2022
Q4 		$12.9M Hold
88,000
– – 0.74% 36
2022
Q3 		$14.9M Hold
88,000
– – 0.78% 35
2022
Q2 		$10.2M Hold
88,000
– – 0.57% 35
2022
Q1 		$8.78M Buy
88,000
+40,000
+83% +$4.67M 0.37% 54
2021
Q4 		$7.46M Hold
48,000
– – 0.22% 82
2021
Q3 		$11.3M Hold
48,000
– – 0.28% 78
2021
Q2 		$16.3M Hold
48,000
– – 0.37% 65
2021
Q1 		$19.4M Hold
48,000
– – 0.41% 68
2020
Q4 		$31.9M Buy
48,000
+8,000
+20% +$4.45M 0.73% 40
2020
Q3 		$18.6M Buy
40,000
+8,000
+25% +$4.04M 0.61% 48
2020
Q2 		$18.7M Buy
+32,000
New +$10.9M 0.64% 45

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $50.9B AUM 42.89% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $849M AUM 470.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return